1. Van Nostrand D, Neutze J, Atkins F. Side effects of “rational dose” iodine-131 therapy for metastatic well-differentiated thyroid carcinoma.J Nucl Med 1986; 27:1519–1527.
2. Lin W, Shen YY, Wang SJ. Short-term hazards of low-dose radioiodine ablation therapy in postsurgical thyroid cancer patients.Clin Nucl Med 1996; 21:780–782.
3. Mazzaferri EL. Radioiodine and other treatments and outcome. In:Werner and Ingbar’s the Thyroid, Braverman L, Utiger RD (eds), Philadelphia; Lippincott-Raven Publishers, 1996: 922–945.
4. Zettinig G, Hanselmayer G, Fueger BJ, Hofmann A, Pirich C, Nepp J, et al. Long-term impairment of the lacrimal glands after radioiodine therapy: a cross-sectional study.Eur J Nucl Med 2002; 29:1428–1432.
5. Bohuslavizki KH, Brenner W, Klutmann S, Hubner RH, Lassmann S, Feyerabend B, et al. Radioprotection of salivary glands by amifostine in high-dose radioiodine therapy.J Nucl Med 1998; 39:1237–1242.